Compare Ondine Biomedical, Inc. with Similar Stocks
Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of -8.47% over the last 5 years
2
Negative results in Dec 25
3
Risky -
4
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
GBP 56 Million (Micro Cap)
23.00
NA
0.00%
-2.94
175.31%
29.48
Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Jun 2011)
Net Profit:
-1 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-27.12%
0%
-27.12%
6 Months
0%
0%
0.0%
1 Year
-28.33%
0%
-28.33%
2 Years
90.94%
0%
90.94%
3 Years
16.22%
0%
16.22%
4 Years
-67.91%
0%
-67.91%
5 Years
-99.43%
0%
-99.43%
Ondine Biomedical, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-8.47%
EBIT Growth (5y)
24.65%
EBIT to Interest (avg)
-20.35
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.42
Sales to Capital Employed (avg)
20.27
Tax Ratio
39.43%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
345.04%
ROE (avg)
123.78%
Valuation key factors
Factor
Value
P/E Ratio
23
Industry P/E
Price to Book Value
40.45
EV to EBIT
22.95
EV to EBITDA
14.70
EV to Capital Employed
-19.31
EV to Sales
1.38
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
175.31%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
1.40
1.20
16.67%
Operating Profit (PBDIT) excl Other Income
-16.00
-10.80
-48.15%
Interest
0.00
0.00
Exceptional Items
0.00
0.20
-100.00%
Consolidate Net Profit
-16.00
-10.90
-46.79%
Operating Profit Margin (Excl OI)
-11,325.40%
-9,489.50%
-183.59%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 16.67% vs 71.43% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -46.79% vs -26.74% in Dec 2024
About Ondine Biomedical, Inc. 
Ondine Biomedical, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






